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ABSTRACT 
 
Niosomes have shown promise as cheap and chemically stable drug delivery 
systems. Niosomes have been prepared with different molar ratios of surfactant and 
cholesterol and their morphological properties have been determined by scanning 
electron microscopy. Different batches of Fluconazole niosomal preparations were 
prepared by changing the surfactant concentration but keeping the cholesterol 
concentration constant. The surfactant used was Span 60 and the five batches of 
niosomal preparations prepared were in the ratios 1:1:1, 1.5:1:1, 2:1:1, 2.5:1:1 and 
3:1:1 (surfactant: cholesterol: drug). Furthermore, the release profile, entrapment 
efficiency, size distribution and stability of these niosomes under various 
temperatures were studied. 
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1. INTRODUCTION 
 
 Current research and development strategy focus on development of 
drug delivery systems that make clinically established drugs do their therapeutic best 
rather than search for new drugs. The aim of any drug delivery system should always 
be to achieve maximum therapeutic response with minimum side effects.  
 Like phospholipids, the nonionic surfactants are able to form vesicular 
delivery systems called “niosomes” when dispersed in water. This is a rather recent 
concept with a few but very important investigations which show that this carrier 
system possesses great potential in delivery of drugs in biological system. They are 
known to be analogous to liposomes, and have been used in cosmetic formulations 
and experimentally as drug carriers1, 2. Niosomal vesicles can encapsulate both 
lipophilic and hydrophilic drugs and protect them against acidic and enzymatic effects 
in vivo3.They offer several advantages over liposomes such as higher chemical 
stability, intrinsic skin penetration enhancing properties and lower costs 4. However, 
there may be problems of physical instability in niosome dispersions during storage 
like vesicles aggregation, fusion, leaking or hydrolysis of encapsulated drugs, which 
might affect the shelf life of the dispersion 5. 
 Fluconazole, an antifungal drug, is available as capsules and 
suspensions. These formulations are used in the effective and safe treatment of 
oropharyngeal candidiasis. The topical effect of fluconazole oral suspension leads to 
an even faster resolution of symptoms. The aim of this study was to develop a 
niosomal drug delivery system for fluconazole , a triazole antifungal drug that acts by 
inhibition of the ergosterol component of the fungal cell membrane, because niosomal 
formulations have better permeability due to the presence of hydrophilic and 
lipophilic moieties. Hence a delivery system based on cholesterol and non ionic 
surfactant may have an advantage in the antifungal activity of fluconazole. 
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2. MATERIALS AND METHODS 
 
2.1. Materials 
 
Cholesterol, Span-60, sodium chloride, disodium hydrogen-phosphate, 
potassium dihydrogen-orthophosphate, sodium dihydrogen-phosphate and acetone 
were procured from Central Drug House Lab Reagents, Delhi, India. Dialysis 
membrane was purchased from Himedia Laboratories Pvt. Ltd; Mumbai, India and 
drug fluconazole was obtained as a gift sample from Idma Laboratories Limited, 
Chandigarh, India. 
 
2.2. Methods  
 
2.2.1. Preparation of niosomes 
 
Niosomes were prepared by slight modification of ether injection 
technique.6Niosomes were prepared using Span-60, cholesterol and fluconazole in the 
ratio (by weight) of 1:1:1; 1.5:1:1; 2:1:1; 2.5:1:1 and 3:1:1, respectively. For each 
ratio, non-ionic surfactant (Span-60) and cholesterol were weighed accurately and 
dissolved in 20 ml of chloroform. Fluconazole (20 mg) was then dissolved in this 
lipid solution. The resulting solution was taken in a syringe and injected slowly 
through a 16 gauge needle into 4 ml of aqueous phase (phosphate buffer pH 7.4) held 
in a beaker maintained at 60-65oC and agitated slowly. As the lipid solution was 
injected slowly into the aqueous phase, vaporization of chloroform resulted in the 
formation of niosomes. These niosmes were filtered through 0.22 µm membrane 
filters after sonication for 20 minutes. The niosomal suspensions were labeled as F1-
F5. The drug content in the niosomal vesicles were estimated by UV spectrophoto 
metrically at λmax 260 nm after disrupting the vesicles using 50% n-propanol.  
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2.2.2. Microscopic evaluation of niosomes 
 
Small amounts of the formed niosomes were spread on a glass slide and 
examined for the vesicular structure and for the presence of insoluble drug crystals 
using ordinary light microscope with 10X magnification powers. The morphology of 
hydrated niosome dispersions prepared by conventional methods was determined 
using transmission electron microscopy. A drop of niosome dispersion was diluted 
10-fold using deionized water. A drop of diluted niosome dispersion was applied to a 
carbon-coated 300 mesh copper grid and left for 1 min to allow some of the niosomes 
to adhere to the carbon substrate. The remaining dispersion was removed by 
absorbing the drop with the corner of a piece of filter paper. After twice rinsing the 
grid (deionized water for 3–5 s) a drop of 2% aqueous solution of uranyl acetate was 
applied for 1 s. The remaining solution was removed by absorbing the liquid with the 
tip of a piece of filter paper and the sample was air dried. The sample was observed 
with a JEOL 100 CX transmission electron microscope at 80 KV. 
 
2.2.3. Determination of entrapment efficiency 
 
Niosomes containing fluconazole were separated from unentrapped drug by 
centrifugation. This purified niosomal dispersion was used for further studies.  The 
niosomal dispersions were centrifuged at 9000 rpm for 30 minutes and the decanted 
fluid was separated from the sediment material i.e. the niosomes containing the 
entrapped drug 5. 
An aliquot of freshly purified fluconazole niosomal dispersion after lysis with 
50% n-propanol was analyzed spectrophotometrically for fluconazole concentration at 
λmax 260 nm to calculate the amount of entrapped fluconazole. The percentage of 
entrapped fluconazole was calculated by applying the following equation. 
                
% entrapment =Ae x100 / Ai 
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Where, Ae is the amount of entrapped drug and Ai is the initial amount drug in 
the lipid phase. 
 
2.2.4. Particle size determination 
 
Niosome size distribution was determined by dynamic light scattering 
(Zetasizer 3, Malvern, UK) at 25 °C. Samples were scattered (633 nm) at an angle of 
90°. Each formulation was measured three times in triplicate during a period of 15 
days. 
 
2.2.5. In vitro drug release 
 
Release of fluconazole from niosomes in vitro was performed according to 
Hu’s method with minor modifications 5. All the formulations were subjected to drug 
release studies 7. A simple niosomal suspension was prepared (F6) for comparison. 
The dissolution cell consisted of a hollow glass cylinder (length 14.6 cm and internal 
diameter 2.5 cm) made up of Borosil glass. One end of the cylinder was covered with 
Himedia dialysis membrane (cut-off molecular weight: 12000-14000), which was 
previously soaked in warm water. The dissolution cell was placed in a 500 ml Borosil 
beaker that served as the receptor cell. The contents of the dissolution cell were 
agitated with the help of a glass stirrer. The receptor cell contained a magnetic bead 
and was rotated at a constant speed. The temperature in the dissolution and receptor 
cells was maintained at 37oC, with the help of a thermostat. Five milliliters of each 
formulation was subjected to release studies. Phosphate buffer saline (100 ml) pH 7.4 
was placed in the receptor cell. A 5 ml sample of each formulation was transferred to 
the dissolution cell. One milliliter samples were withdrawn from the receptor cell at 
specified time intervals of 0.25, 0.5, 1, 2, 4, 8, 12 and 24 h. At each time immediately 
after the removal of the sample, the medium was compensated with fresh phosphate 
buffer saline (pH 7.4). The samples were analyzed for fluconazole content using a UV 
spectrophotometer (Shimadzu UV-160, Japan) at λmax 260 nm. 
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To investigate the possible mechanisms of fluconazole release from the 
prepared niosomes, the release data were analyzed mathematically according to the 
following models. 
 Q = kt 
 Log Q = kt/2.303 
 Q = k√t 
Where, Q is the amount of drug released at a time (t) and k is the rate constant.   
The cumulative percent release of fluconazole for all the batches was 
calculated and the data analyzed for release kinetics. Then the optimized batch was 
selected based on statistical inference and the optimized batch was compared with a 
niosomal oral suspension for its percent cumulative release. 
 
2.3 Stability studies 
The stability studies of the optimized niosomal formulation (F-2) were 
performed at different conditions of temperature and the effect on physical 
characteristics and drug content was noted. The niosomal dispersions (5.115 mg 
fluconazole /5ml) were kept in the air tight containers and stored at 2-8oC and at room 
temperature (30 ± 2oC) for 28 days and the 5.0 ml samples were withdrawn on 
different days (7, 14, 21 and 28). The samples were analyzed spectrophotometrically 
at λmax 260 nm after disrupting the vesicles with 50% n-propanol. 
Table 1: Average particle size of fluconazole niosomes with varying concentrations of 
surfactant 
Surfactant: Cholesterol: 
Drug 
Mean Diameter 
(nm) 
1:1:1 78.87±175 
1.5:1:1 74.46±1.65 
2:1T1 76.07±2.25 
2.5:1:1 73.39±1.95 
3T1T1 70.17±1.25 
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Table 2: Entrapment efficiency of niosomes with varying drug, surfactant, and 
cholesterol ratios 
Surfactant: Cholesterol: Drug % Entarpment of Fluconazole 
1:01:01 92.71±0.43 
1.5:1:1 92.27±0.52 
2:01:01 93.18±0.37 
2.5:1:1 91.36±0.98 
3:01:01 91.81±0.73 
 
Table 3: Release rate constants (k) and correlation coefficients (r) of niosomes 
Formulation 
Zero Order Release 
Model 
First Order 
Release Model 
Higuchi Release 
Model 
k (%h-1) r k (h-1) r k (h-1/2) r 
F-1 0.964 0.801 0.008 0.781 11.600 0.865 
F-2 1.467 0.968 0.018 0.867 13.243 0.903 
F-3 1.250 0.905 0.014 0.815 11.748 0.853 
F-4 1.196 0.919 0.016 0.839 12.554 0.891 
F-5 1.019 0.880 0.007 0.789 11.477 0.837 
F-6 1.285 0.723 0.007 0.703 22.996 0.876 
 
3. RESULTS AND DISCUSSION 
3.1 Microscopic evaluation of niosomes 
Transmission electron microscopy (Fig-1) was used for microscopic 
evaluation of niosomal dispersions prepared by ether injection and it shows that 
niosomes formed by direct hydration are very heterogeneous and were both 
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unilamellar and multilamellar in their structures. Inverted microscopic evaluation 
(Fig-2) showed that most of the niosomes were mostly spherical in shape with a few 
being triangular, somewhat oval or slightly elongated and larger in size.  
3.2 Determination of particle size and entrapment efficiency 
Fluconazole niosomes prepared by ether injection technique employing 
varying ratios of surfactant (Span 60), cholesterol and drug were found to be spherical 
in shape. The average size of niosomes is reported in Table-1. The entrapment 
efficiency of drug was more than 91% with all the niosomal preparations as shown in 
Table-2. Cholesterol containing niosomes show higher entrapment because 
cholesterol alters the fluidity of chains in bilayer 8. 
 
 
 
   
 
 
 
 
 
Fig.1: Transmission Electron Micrograph (TEM) of fluconazole the niosomes  
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                    Fig.2: Inverted microscope photomicrographs of niosomes 
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Fig.3: Cumulative fluconazole release of niosomal formulations 
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Comparative % CR of optimized niosomal formulation 
and non-niosomal suspension 
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Fig.4: Comparative % CR of optimized niosomal formulation and non-niosomal 
suspension 
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Fig.5: Mean size of niosomes at 2-8ºC and room temperature 
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Effect of different storage temperature conditions on drug 
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Fig.6: Effect of different storage temperature conditions on drug entrapment of oral 
niosomal suspension of fluconazole 
 
3.3 In vitro drug release 
To predict the release pattern of fluconazole from niosomal formulation 
batches (F-1 and F-5) correlation coefficient (Table-3) was calculated for zero order 
and first order kinetics. The release profiles of fluconazole from niosomes of different 
surfactant contents were apparently biphasic processes.   The release pattern of F-2 is 
also the desired experimental release pattern expected i.e. sustained release matrix 
type. Therefore F-2 was an optimized batch and a comparative study of release pattern 
of F-2 with the prepared oral suspension showed significantly low cumulative release 
at every sampling interval. So it can be concluded that the fluconazole niosomal oral 
suspension is showing a slow and retarded release with no dose dumping in the 
dissolution media. 
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3.5 Stability Studies 
 Mean size determination and drug entrapped in niosomes at different 
temperature and stress are selected to establish the stability profile of the optimized 
formulation (F-2).  
Mean particle size at different temperature was determined at weakly intervals 
for 28 days. Size fluctuations were observed though no aggregation of niosomes could 
be seen on storage. To determine stability, Fluconazole niosomal preparations were 
stored at 2-8ºC and at room temperature (Fig-4). Although the mean size varied, there 
was no tendency towards increased aggregation and the storage temperature had little 
effect on particle size. Although mean size was seen to fluctuate, no substantial 
aggregation was seen. These experiments reveal that the Span 60 niosome 
formulations described herein are generally very stable. Storage at expensive sub-
ambient temperatures offers no advantage and as Span 60 has a high phase transition 
temperature of 50oC 9, room temperature would offer a suitable impermeable system 
for fluconazole entrapment.  
                Fluconazole niosomes were stored as the purified suspension with 
the unentrapped material removed by centrifugation, initially there was loss in 
fluconazole content within first seven days; there after the level of fluconazole  
fluctuate but not significantly (Fig-5). Purified niosomes retain a great proportion of 
associated fluconazole on storage and it is difficult to explain initial loss seen as this 
in not simply an osmotic effect and it is unlikely the sufficient drug is associated 
loosely with the niosomal membrane. The drug content in niosomal formulation is 
higher at temperature 2-8ºC than at RT (30±2ºC) 
4. CONCLUSIONS 
Fluconazole was successfully encapsulated into niosomes by ether injection 
method, which showed that it was an appropriate alternative technique to load 
fluconazole into lipid vesicles. Niosomes offer advantages over other drug carriers 
with respect to biocompatibility, ease of preparation and their capacity to carry large 
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amount of drugs. The results reveal that niosomes are comparatively stable at lower 
temperatures. Thus on the basis of studies conducted we can state that niosomes 
possess great potential as drug delivery carriers and hence the formulated fluconazole 
niosomal suspension can be further evaluated for its in vivo performance. 
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